Compliance-first framework pairs SynGenic V3™ technology with Salem's power development and operating experience, beginning with U.S. sanctions and export-control clearanceMiami,...
Image-Quality Pass Rate of 84%, Boundary Stability of 87% and Sequential Alignment Completion of 91% on Controlled Captures as Models...
WOONSOCKET, RI / ACCESS Newswire / October 12, 2026 / Originally published on CVS Health Company NewsroomKey pointsLong waits, rising...
Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 /...
Experienced CRO leader brings deep scientific, commercial and operational expertise to lead the company’s next phase of growthCHAPEL-EN-LE-FRITH, United Kingdom,...
Two oral presentations at AHA Hypertension 2026 demonstrate the pronounced efficacy of aprocitentan in two groups of patients with notoriously...
Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold TumorsNANJING, China, Oct. 12, 2026 (GLOBE NEWSWIRE)...
BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody...
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic...
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal...
41% of CSB-001 treated eyes gained ≥15 letters compared to 0% in the non-treatment arm 55% of CSB-001 treated eyes...
LAS VEGAS, NV, Oct. 11, 2026 (GLOBE NEWSWIRE) -- Using FDA-cleared Cleerly AI analysis of coronary CT angiography, LV Longevity...
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 -...
In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with...
TAMPA, Fla., Oct. 11, 2026 /PRNewswire/ -- Blue Purpose, a technology and data warehousing company focused on transforming long-term care...
Fifth-year, 340-page guide offers free access to country-by-country intelligence on EHR adoption, implementation challenges and healthcare technology opportunities through 2030....
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with...
New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systemsHIGH POINT, N.C., Oct. 10,...
BOULDER, Colo., Oct. 10, 2026 (GLOBE NEWSWIRE) -- Corza Medical, a leading global medical technology company, today announced the launch...